biostudies-literatureUnknown13Zhou Y<h4>Introduction</h4>Antibodies to MuSK identify a rare subtype of myasthenia gravis (MuSK-MG). In western countries, the onset age of MuSK-MG peaks in the late 30's while it is unknown in Chinese population.<h4>Methods</h4>In this retrospective multicenter study, we screened 69 MuSK-MG patients from 2042 MG patients in five tertiary referral centers in China from October 2016 to October 2021 and summarized the clinical features and treatment outcomes. Then we subgrouped the patients into early-onset (<50 years old), late-onset (50-64 years old), and very-late-onset (≥65 years old) MG and compared the differences in weakness distribution, disease progression and treatment outcomes among three subgroups.<h4>Results</h4>The patients with MuSK-MG were female-dominant (55/69) and their mean agFrontiers in neurology879261https://www.ebi.ac.uk/biostudies/studies/S-EPMC9033288biostudies-literatureClinical Features of Myasthenia Gravis With Antibodies to MuSK Based on Age at Onset: A Multicenter Retrospective Study in China.PMC9033288Zhou LZhao CChen JHuan XZhou YZeng WSong JXi JLi ZTan SYan CLuo SWang YfalseClinical Features of Myasthenia Gravis With Antibodies to MuSK Based on Age at Onset: A Multicenter Retrospective Study in China.<h4>Introduction</h4>Antibodies to MuSK identify a rare subtype of myasthenia gravis (MuSK-MG). In western countries, the onset age of MuSK-MG peaks in the late 30's while it is unknown in Chinese population.<h4>Methods</h4>In this retrospective multicenter study, we screened 69 MuSK-MG patients from 2042 MG patients in five tertiary referral centers in China from October 2016 to October 2021 and summarized the clinical features and treatment outcomes. Then we subgrouped the patients into early-onset (<50 years old), late-onset (50-64 years old), and very-late-onset (≥65 years old) MG and compared the differences in weakness distribution, disease progression and treatment outcomes among three subgroups.<h4>Results</h4>The patients with MuSK-MG were female-dominant (55/69) and their mean ag2022-01-01T00:00:00Z20222025-06-01T02:56:50.06Z2025-06-01T02:56:50.06ZS-EPMC90332883546313810.3389/fneur.2022.879261